Coronavirus, Covid19, SARS-CoV 2
Conditions
Keywords
Immunology, Innate Immune System
Brief summary
QuadraMune(TM) is a nutritional supplement which has previously been demonstrated to possess antiinflammatory and immune modulatory activity based on in vitro and pilot in vivo studies. The current clinical trial aims to assess in a 500 volunteer trial the efficacy of QuadraMune(TM) in reducing infection in individuals at high risk of COVID-19.
Detailed description
QuadraMune(TM) is composed of 4 natural ingredients. Pterostilbene is an analogue of resveratrol, and has been shown to possess antiinflammatory activity. Additionally, this compound suppresses macrophage activation while enhancing NK activity. Epigallocatechin gallate (EGCG) is one of the active ingredients in green tea and has been shown to act as an activator of T cells, and a suppressor of neutrophil mediated inflammation. Sulforaphane is derived from broccoli and studies have shown that it protects lungs from inflammatory pathology. Thymoquinone, which is chemically related to hydroxychloroquine, possessing antiviral effects and increases NK activity. QuadraMune is a combination of these ingredients and is believed to possess superior in vitro and in vivo therapeutic properties as compared to when the ingredients are administered individually. The study aims to assess preventative effects of QuadraMune(TM) administration for 12 weeks.
Interventions
DIETARY_SUPPLEMENTQuadraMune(TM)
QuadraMune(TM) is a commercially available nutritional supplement
Sponsors
Therapeutic Solutions International
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
Yes
Inclusion criteria
* Informed consent, provided electronically via the EDC, demonstrating the subject understands the procedures required for the study and the purpose of the study Male or female patients 18 years of age or older that are considered to be high-risk individuals. * High-risk individuals are defined as all health care workers in hospitals, clinics, and emergency rooms, and medical facilities. * Subjects must agree to practice at least two highly effective methods of birth control for the duration of the study This includes condoms with spermicide, oral birth control pills, contraceptive implants, intra-uterine devices, or diaphragms. At least one of these must be a barrier method. Subjects not of reproductive potential will be exempt (e.g. post-menopausal, surgically sterilized)
Exclusion criteria
* Refusal to provide informed consent Any previous positive test for COVID-19 by RT-PCR Symptomatic for COVID-19 Diarrhea prior to the start of treatment Type I or II diabetes Atherosclerotic Coronary Artery Disease Any contraindication for treatment with hydroxychloroquine including: Hypoglycemia G6PD deficiency Porphyria Anemia Neutropenia Alcoholism Myasthenia Gravis Skeletal muscle disorder Maculopathy Changes in the visual field Liver disease, with ALT/AST \> 2.5 upper limit normal and total bilirubin \>2.5 upper limit normal Psoriasis Any comorbidities which, in the opinion of the investigator, constitute health risk for the subject.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevention of COVID-19 | 12 Weeks | Prevention of COVID-19 symptoms as recorded in a daily diary |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety as determined by presence or absence of Adverse Events and Serious Adverse Events | 12 Weeks | Assessment of adverse events and serious adverse events will be performed. |
Countries
United States
Contacts
Primary ContactThomas E Ichim, Ph.D
Outcome results
None listed